CD274 and non-small cell lung carcinoma: In addition to molecularly targeted therapies, immunotherapies have also improved treatment for non-small cell lung cancer (NSCLC), providing survival benefits for patients with metastatic NSCLC regardless of their PD-L1 expression level [8].